- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Spatial distribution of Parkinson's disease mortality in Spain, 1989-1998, as a guide for focused aetiological research or health-care intervention
© Pedro-Cuesta et al; licensee BioMed Central Ltd. 2009
Received: 18 June 2009
Accepted: 2 December 2009
Published: 2 December 2009
Aetiologically, genetic and environmental factors having an uneven spatial distribution may underlie Parkinson's disease (PD). Undiagnosis of PD in selected regions might have limited access to treatment with levodopa and simultaneously, if present at death, determined PD underreporting at the death record. The purpose of this study was to describe and analyse municipal mortality due to PD in Spain in aetiological and interventional perspective.
PD mortality at a municipal level was modelled using the Besag-York- Molliè autoregressive spatial model, combining demographic information with cause-of-death diagnostic data (International Classification of Diseases 9th Revision (ICD-9) code 332.0). Municipal relative risks (RRs) were independently estimated for women, men and both sexes, and plotted on maps depicting smoothed RR estimates and the distribution of the posterior probability of RR>1.
A south-north gradient, with large geographical areas suggesting clustered towns with high mortality, was seen in Asturias, the Basque Country, Balearic Islands and, particularly, in the Lower Ebro valley around Tarragona. Similarly, there was a suggestion that lowest mortality was clustered in the south-east and south-west. We identified some isolated or clustered municipalities with high mortality that were situated near industrial plants reported to be associated with environmental xenobiotic emissions. However, the same pattern was also observed for some cities with low mortality.
Municipal PD mortality in Spain was unevenly distributed. Patterns were roughly similar to reported provincial PD mortality and use of levodopa. While the overall pattern appears to result from spatially selective PD undiagnosis, and can not be ascribed to industrial emissions, it can not be excluded that selected "hot spots" reflect genetic factors and/or environmental exposures inducing parkinsonism. A few municipal populations, located in low-mortality-risk areas in the vicinity of polluting plants or registering high excess PD mortality, might constitute a priority for conducting direct etiological studies. Additionally, interventions aimed to reduce potential PD undiagnosis might be most appropriate in the South.
The purpose of this study was to detect spatially uneven mortality from Parkinson's disease (PD) in Spain as a tool potentially useful for design of focused etiological research and interventions aimed to reduce possible PD undiagnosis and undertreatment. The first aim requires a detailed positioning with regard to causality in PD. The second one, will consider comparisons with geographical patterns of levodopa use (LDU).
The aetiology of the most common forms of Parkinson's Disease (PD), whether sporadic or familial, is poorly understood. Genetic heterogeneity, with at least eight susceptibility loci, has been implicated in rare, monogenic, familial forms . Nevertheless, low concordance in twins , familial-aggregation patterns , birth-cohort effects , and the results of diverse genome-wide linkage and association studies [1, 5, 6], albeit debated, support the contention that the large majority of sporadic PD cases result from a synergistic effect of multigenic inheritance and environmental factors. The nature of Lewy bodies, a hallmark of late-onset PD neurodegeneration, consisting of deposits of aggregated misfolded α-synuclein and other proteins through the dysfunctioning of α-synuclein and other genes, may, in part, have elucidated molecular phenomena responsible for monogenic familial and some sporadic PD forms [7, 8]. Exposure to combined environmental chemicals, such as pesticides and metals, may alter α-synuclein and dopaminergic function in the substantia nigra [9–12]. In addition, a mitochondrial complex I function defect --described in brain tissue and platelets of patients affected by sporadic PD-- has been proposed as a plausible pathophysiological apoptotic mechanism shared by most PD forms [13–15]. Through activation of apoptotic molecular pathways, mitochondrial poisons, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone, lead to degeneration of substantia nigra pars compacta, of a type similar to that seen in PD [16, 17]. Likewise, many other oxidative stress-inducing agents lead to activation of mitochondrial apoptotic pathways . Recently-published animal model studies are consistent with a complex aetiology for late-onset PD, i.e., multigenic susceptibility paving the way for a neurodevelopmental basis plus environmental toxic multi-insults or ageing . However, evidence from PD natural history or epidemiology which supports specific steps, is sparse.
Clinical and experimental MPTP observations in the early 1980s fuelled the search for environmental toxins potentially implicated in PD; paraquat, a herbicide chemically similar to MPTP, was perhaps the first of a series of such hypotheses relating to various manmade toxins, with pesticides being by far the most frequently investigated [9, 10, 12, 19]. A detailed review of five cohort studies, 38 separate case-control studies and one meta-analysis on pesticide risk, supported by even more recent findings , concluded that there does indeed appear to be evidence of a potential role of pesticides in the development of PD, with the current body of evidence being insufficient to establish causation for any specific pesticide . Conversely, an ubiquitous natural toxin, Pertussis toxin, mediated by high age at infection, or dietary exposure to marine food contaminants has been proposed as aetiological environmental factors explaining birth-cohort effects in Iceland and high PD prevalence in geographical isolates, i.e., in Iceland, Greenland and the Faroe Islands [19, 22, 23].
Studies able to indicate geographical regions with a potentially high incidence of PD can be crucial for planning analytical surveys or case-control studies aimed at testing specific hypotheses on industrial pollutants, such as pesticides, insecticides and heavy metals claimed to be potentially relevant for the disorder . The publication of European Pollutant Emission Register-Spain (EPER-Spain) data enables the presence of geographical patterns linked to industrial pollution to be investigated [25, 26]. In Europe, Spain has been the leading polluter in almost one third of all EPER pollutant substances released into the environment, and ranks among the top three leading polluters in two-thirds of all such substances. In addition use of pesticides in agriculture has been historically important in Spain. For a number of years, however, the only nation-wide source of PD diagnostic and residential data has been the cause-of-death registry. A recent disease-mapping mortality study in Spain, in which PD was included, disclosed an unexpected spatial pattern for this disorder .
This paper thus sought to: describe and map the municipal distribution of parkinsonism-related mortality in Spain; discuss possible determinants of patterns; and indicate the most promising study populations for the purpose of undertaking direct studies (which tend to be expensive) aimed at investigating the relationship between industrial pollutant emissions and PD or to reduce PD undiagnosis. This study did not quantitatively analyse the relationship between industrial pollutants and PD mortality.
Spanish municipal populations, broken down by age group (18 groups) and sex, were obtained from the 1991 census and 1996 municipal roll. These years correspond to the midpoints of the two quinquennia that comprise the study period (1989-1993 and 1994-1998). The person-years for each five-year period were obtained by multiplying these populations by 5.
For our case source, we used individual death entries for the period 1989-1998, corresponding to Parkinson's disease (International Classification of Diseases 9th Revision (ICD-9) code 332.0) as the underlying cause of death, broken down by town or city, nation-wide. These data were furnished by the National Statistics Institute (Instituto Nacional de Estadística - INE) for the production of a municipal cancer mortality atlas of which these results form part .
Standardised mortality ratios (SMRs) were calculated as the ratio of observed to expected deaths. For the calculation of expected cases, the overall Spanish mortality rates for the above two 5-year periods were multiplied by each town's person-years, by age group, sex and quinquennium.
For map-plotting purposes, smoothed municipal relative risks (RRs) were calculated, using the conditional autoregressive model proposed by Besag, York and Molliè (BYM). This model was introduced by Clayton and Kaldor , developed by BYM , and subsequently applied in the field of ecological studies . These models are based on fitting Poisson spatial models with observed cases as the dependent variable, expected cases as offset, and two types of random effects terms which take the following into account: a) municipal contiguity (spatial term); and b) municipal heterogeneity. The models were fitted using Markov chain Monte Carlo simulation methods with non-informative priors . Posterior distributions of relative risk were obtained using WinBugs . The criterion of contiguity used was adjacency of municipal boundaries. Convergence of the simulations was verified using the Bayesian Output Analysis (BOA) R programme library . Given the great number of parameters of the models, the convergence analysis was performed on a randomly selected sample of 10 towns and cities, taking 4 strata defined by municipal size. Convergence of the estimators was achieved before 100,000 iterations. For the maps shown, a "burn-in" (iterations discarded to ensure convergence) of 300,000 iterations was performed and the posterior distribution was derived with 5,000.
A Geographic Information System was used to plot municipal maps that depicted smoothed RR estimates and the distribution of the posterior probability (pp) that RR>1 (Bayesian version of p value). With regard to this indicator, we followed Richardson's criterion , which recommends that probabilities above 0.8 should be deemed significant.
Results and Discussion
Summaries of population and PD mortality in Spain's 8077 towns: 1989-1998.
No. (%) of areas with zero counts
While the most striking spatial high-mortality pattern corresponded to the north-eastern area of the Lower Ebro valley in Catalonia, centred on Tarragona, the lowest mortality was observed in the south-east, in an area covering part of the provinces of Jaén, Granada, Almería, Albacete and Murcia, and in the south-west, in the provinces of Seville and Cadiz. All three patterns would suggest a clustering of several municipalities. Other large geographic areas to register the highest mortality were located in northern provinces, in regions such as Asturias and the Basque Country, as well as in the Balearic Islands.
Municipalities with 10 or more observed deaths due to Parkinson Disease, RRs >= 1.3 and a posterior probability >= 0.80 of having an RR greater than 1.
Observed number of deaths
Expected number of deaths
Mieres del Camino*
San Martín del Rey Aurelio
Santa Eulalia del Río
Montcada I Reixac*
Cerdanyola del Vallès*
Vilafranca del Penedès*
Vilanova I la Geltrú*
A Coruña (Corunna)
Santiago de Compostela
Arrasate O Mondragon
Pozuelo de Alarcón
Towns with lower-than-expected PD mortality. Towns with 5 or more expected deaths from Parkinsonism and a posterior probability <= 0.10 of having an RR greater than 1
Observed number of deaths
Expected number of deaths
Alfaz del Pi
Hospitalet de Llobregat (L')
Sant Feliu de Llobregat*
Miranda de Ebro*
Arcos de La Frontera*
Chiclana de La Frontera
Jerez de La Frontera*
Sanlúcar de Barrameda
Castellón de La Plana/Castello*
Valverde del Camino
Alcalá la Real
Caravaca de La Cruz
Alcalá de Guadaira*
Morón de La Frontera*
To our knowledge, this study is the first ever attempt to disclose differences in the spatial distribution of PD mortality in populations resident in small areas nation-wide. Results suggest that there is a considerable variation, with a south-north gradient and some potential clusters. Differences should be associated with PD or PD-like disorders, since PD is the most frequent type of parkinsonism. Nevertheless, they could be explained by other multiple single or combined factors, such as ascertainment, reporting, or specific aetiological factors, including potential exposure to environmental contaminants and persistent organic pollutants in particular.
Mortality statistics on PD are difficult to interpret because reporting bias may not only be frequent but may also change with time and place. A review  pertinent to our study period reported that: 1) in clinical series, the proportion of PD sufferers whose death certificates made no mention of the disease ranged from 68% in Iceland to 81% in Rochester; and 2) in those cases where PD was reported, the annual proportion recorded as the underlying cause of death in Sweden ranged from 46% to 81%, and varied by county. The shift that took place in Sweden in the early 1980s from recording PD as a contributory cause of death to recording it as the underlying cause of death, was attributed to late implementation of a World Health Organisation (WHO) recommendation: even if this had been present in Spain, where the underlying cause of death was studied, it nevertheless occurred before our study period and so could not affect these results. Changes in death-certificate coding of PD during the study period would generate an effect perceived at the level of administrative regional boundaries, something that is not seen in the maps. An internationally described PD mortality pattern, observed for instance in the USA, Sweden, the UK and Spain, corresponds to an ubiquitous increase with advanced age and a decrease at lower ages . In Spain, age-period-cohort analysis revealed an increase in both sexes as a period effect since 1970, and as an inverted-U cohort effect with highest mortalities for cohorts born around 1910 and lowest mortalities in recently-born cohorts . We propose that, since mapped PD mortality would mainly reflect mortality among the elderly, the geographical pattern might be principally determined by specific changes across time-spatially sensitive, i.e., non-simultaneous, improvement in medical services in terms of diagnosing late-onset PD.
Since prevalent undiagnosed PD as seen from Spanish population screening surveys ranged from 12% to 69% , and PD incidence in a Spanish population aged 65 years and over  was ten times higher than PD mortality yielded by our study, PD diagnosis reported at death probably had a low sensitivity for PD. Low death-record sensitivity for PD might be due to low PD ascertainment at death, low reporting bias or low mortality/fatality of PD patients. Since all-cause mortality in the general population is higher in the south , it would seem difficult to explain the south-north pattern in terms of the effect of high general mortality on PD patients.
Despite the fact that a higher incidence of PD among men has been documented in a Spanish population , the similar geographical mortality pattern among men and women (not shown here) would point to causes of geographical variation determined by incidence unconnected with occupation. It would be difficult for differential misdiagnosis of PD, such as overdiagnosis (i.e., low specificity), to underlie spatial variation, since PD-like forms of parkinsonism are excluded as a potential explanation due to their considerably lower prevalence [Spanish Group for Epidemiological Study of the Aged, unreported].
Door-to-door PD prevalence surveys have been conducted on four Spanish populations [41–45]. All of these displayed medium prevalence, except the town of Cantalejo in the Province of Segovia, where the high prevalence detected among the elderly segment aged over 80 years was attributed to detailed and intensive case-finding . None of these populations was located in any of the mortality "hot spots" identified by us. Neither unreported PD surveys conducted in the Hondarribia district in the Basque Country , Arosa Island.  and selected subpopulations in Central Spain with medium prevalences [Spanish Groups for Epidemiological Study of the Aged, unreported], nor a survey based on diagnoses collected by the medical services in Lower Aragon, a region lying close to the north-eastern cluster , are of any help when it comes to interpreting our mortality findings for specific towns.
While EPER industries were located in the vicinity of many towns with high or low PD mortality, the excess mortality registered in many towns in Catalonia, the Basque Country, Huesca, Asturias and Tarragona is consistent with the traditional, well-documented industrial toxic emissions reported in these places [26, 27]. The mortality cluster in the Province of Tarragona warrants special attention, since the province encompasses the easternmost stretch of the Ebro basin which historically accumulated the industrial pollution borne by the Ebro River, potentially acting via water and, essentially, through the food chain and diet. Tens of thousands of tons of waste, consisting mainly of several hexachlorocyclohexane (HCH) isomers, were dumped near factories in the Basque Country and the Province of Huesca, namely, in Barakaldo from 1947-1987, in Erandio from 1952-1982 and in Sabiñanigo, with the HCH isomers being disseminated by lixiviation and environmental conditions, and being detected in tributaries of the Ebro River . For over a century, an electrochemical plant and a chemical factory located at Flix have polluted the river and the region with organochlorine compounds and mercury. This pollution has been detected in the ecosystems of the Ebro River delta area [50, 51] and in human serum [52, 53], with high levels of hexachlorobenzene and other organochlorine compounds being found during pregnancy and in cord blood [54–56]. Despite the fact that the chemical factories and waste areas are situated close to or not very far from the PD "hot spots" described here, our findings align better with historical exposures of the type reported in the EPER involving emissions from multiple industrial plants near the city of Tarragona, in which lead, cadmium and other organic and inorganic industrial chemicals are included .
However, some results for PD mortality clusters also deviate from biologically expected patterns. Firstly, low PD mortality is seen in environmentally polluted areas, such as in Huelva, or in the Gibraltar area in southern Spain where both cancer mortality and registered industrial pollution are high [26–28, 58]. Secondly, the lack of excess cancer mortality seen in towns in the Province of Tarragona is difficult to reconcile with high, historically long-lasting industrial pollution and high PD mortality. Third, the lower mortality in Benidorm and the Canary Islands contrasts with the high mortality in the Balearic Islands where the possible weight of the foreign, aged, European resident population should be considered.
Attempts have occasionally been made to link parkinsonism to industrial pollutants but hypotheses (those targeting heavy metals being frequently mentioned) lack confirmation, generally as well as specifically, in the form of recent gene-environment interaction analysis . Manganese, carbon disulphide, carbon monoxide after acute poisoning, cyanide, n-hexane and other chemical toxicity may include features mimicking parkinsonism [60–62]. Exposure to β-HCH has recently been reported as a risk factor for PD . Were one to speculate, PD mortality clusters in northern Spain and Catalonia might be consistent with Gorell et al's hypothesis, suggesting that there is a large array of compounds that may alter the nigrostriatal dopaminergic pathway and induce neural oxidative stress, leading to the development of PD  in which the reported effects of ubiquitous organohalogen xenobiotics --mainly organochlorines-- and polychlorinated biphenyls (PCBs) might be implicated [11, 63–66]. In contrast, a few of the above-mentioned towns with high mortality deserve particular attention because they were located in areas of low industrial activity and low PD mortality, displaying a history of isolated and selective environmental industrial pollution at a distance of less than 2 km from their municipal centroids, such as Jerez de los Caballeros (Badajoz) in the south-east and Alcalá de Henares (Madrid) in central Spain [25, 26]. While familial parkinsonism similar to that found in a small community in the Province of Soria  might account for isolated spots of high PD mortality, the towns with high mortality listed in Table 2 have larger populations. However, there are other reasons for caution, particularly when interpreting such high mortality values in industrial areas. Because EPER facilities are registered insofar as the emissions levels exceed certain threshold levels, absence of EPER facilities in the database does not necessarily mean that industrial emissions are low. In several countries or regions within the EU, there might be a concentration of small to medium size industries, none attaining the threshold for any single pollutant, and where cumulative total emissions are high. Hence caution should be given not to equate absence of EPER facility in a given city and "low industrial activity". In summary, high mortality and absence of EPER registered facility does not exclude a concealed local positive association. To add, SMR values are affected by population size in the town targeted.
Undiagnosed PD present until death, determining PD underreporting at death certificate and low PD mortality, should be suspected as a health-relevant explanation of the lowest PD mortality observed in two broad areas, one covering tracts of several provinces in the south-east, such as Granada, Jaén and Almería, and another in the south-west corresponding to Seville and Cadiz. Such areas displayed some of the lowest LDU rates from 1990 to 1995 , a period encompassed by our own study period, and  the low PD mortality might also indicate historically-persistent low access to PD diagnosis and treatment in such regions, perhaps determined by lack of neurologists at district hospital clinics in Andalucia. Several large towns situated in the above-mentioned and other north-eastern provinces pinpointed in Figure 3 or in neighbouring areas, might be proposed for primary care intervention using reported procedures designed to uncover the potential limitations of medical services in diagnosing and treating PD [68, 69].
Internal migration during the 1960s and 1970s to Madrid, Catalonia/Barcelona and the Basque Country from poor rural areas mainly located South and West , fitting well with regions with low LDU and PD mortality, would have induced patterns opposite to those observed. Neuroepidemiological PD research in such areas is still sparse.
This study provides a summarised report of spatial patterns of municipal PD mortality roughly fitting those of reported provincial mortality and levodopa use, with municipal "hot spots", whether or not clustered, indicating populations of possible interest for direct studies, purpose-designed to test specific PD aetiological hypotheses or improving access to PD diagnosis and treatment.
The authors would like to thank Javier Almazán, Javier Garcia and Enrique Alcalde for their support with the graphs, unpublished reports and editorial work, and JA Burguera for supplying detailed data from reference no. 39. The study was supported by the Spanish Consortia for Biomedical Research in Neurodegenerative Diseases (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas - CIBERNED) and Epidemiology & Public Health (Centro de Investigación Biomédica sobre Epidemiología y Salud Pública - CIBERESP), and by Grant No. EPY-1176/02 from the Carlos III Institute of Health (Instituto de Salud Carlos III - ISCIII).
- Martínez M, Brice A, Vaughan JR, Zimprich A, Breteler BMM, Meco G, et al: Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. J Med Genet. 2004, 41: 900-907. 10.1136/jmg.2004.022632.View ArticlePubMedPubMed CentralGoogle Scholar
- Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Petzinger GM, Widner H, et al: Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging. 2008, 29: 1765-1773. 10.1016/j.neurobiolaging.2007.04.009.View ArticlePubMedGoogle Scholar
- Sveinbjörnsdottir S, Hicks A, Jónsson T, Pétursson H, Guðmundsson G, Frigge M, et al: Familial aggregation of Parkinson's disease in Iceland. N Engl J Med. 2000, 343: 1765-1770. 10.1056/NEJM200012143432404.View ArticlePubMedGoogle Scholar
- de Pedro-Cuesta J, Petersen IJ, Stawiarz L: High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology?. Acta Neurol Scand. 1995, 91: 79-88.View ArticlePubMedGoogle Scholar
- Clarimon J, Scholz S, Fung HC, Hardy J, Eerola J, Hellström O, et al: Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. Am J Hum Genet. 2006, 78: 1082-1084. 10.1086/504727.View ArticlePubMedPubMed CentralGoogle Scholar
- Maraganore DM, de AM, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, et al: High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005, 77: 685-693. 10.1086/496902.View ArticlePubMedPubMed CentralGoogle Scholar
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.View ArticlePubMedGoogle Scholar
- Gasser T: Mendelian forms of Parkinson's disease. Biochim Biophys Acta. 2009, 1792 (7): 587-96.View ArticlePubMedGoogle Scholar
- Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D: Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health. 2000, 59: 229-234. 10.1080/009841000156907.View ArticleGoogle Scholar
- Gorell JM, Peterson EL, Rybicki BA, Johnsson CC: Multiple risk factor in Parkinson's disease. J Neurol Sci. 2004, 217: 169-174. 10.1016/j.jns.2003.09.014.View ArticlePubMedGoogle Scholar
- Mariussen E, Fonnum F: Neurochemical targets and behavioral effects of organohalogen compounds: An update. Crit Rev Toxicol. 2006, 36: 253-289. 10.1080/10408440500534164.View ArticlePubMedGoogle Scholar
- Petersen MS, Halling J, Bech S, Wermuth L, Weihe P, Nuielsen F, et al: Impact of dietary exposure to food contaminants on the risk of Parkinson's disease. Neurotoxicology. 2008, 29: 584-590. 10.1016/j.neuro.2008.03.001.View ArticlePubMedGoogle Scholar
- Parker WD, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989, 26: 719-723. 10.1002/ana.410260606.View ArticlePubMedGoogle Scholar
- Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 1990, 54: 823-827. 10.1111/j.1471-4159.1990.tb02325.x.View ArticlePubMedGoogle Scholar
- Keeney PM, Xie J, Capaldi RA, Bennett JP: Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006, 26: 5256-5264. 10.1523/JNEUROSCI.0984-06.2006.View ArticlePubMedGoogle Scholar
- Vila M, Przedborski S: Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci. 2003, 4: 365-375. 10.1038/nrn1100.View ArticlePubMedGoogle Scholar
- Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V, et al: Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA. 2005, 102: 19126-19131. 10.1073/pnas.0508215102.View ArticlePubMedPubMed CentralGoogle Scholar
- Barlow BK, Cory-Slechta DC, Richfield EK, Thiruchelvam M: The gestational environment and Parkinson's Disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reproductive Toxicology. 2007, 23: 457-470. 10.1016/j.reprotox.2007.01.007.View ArticlePubMedGoogle Scholar
- Langston JW, Ballard PA, Tetrud JW, Irwin I: Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science. 1983, 219: 979-980. 10.1126/science.6823561.View ArticlePubMedGoogle Scholar
- Dick FD, Seaton A, Haites N, Semple SE, Dick S, Prescott GJ, et al: Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2007, 64: 666-672. 10.1136/oem.2006.027003.View ArticlePubMedPubMed CentralGoogle Scholar
- MRC Institute for Environment and Health. Pesticides and Parkinson's Disease -- A Critical Review (Web Report W21). 2009, Ref Type: Electronic Citation, [http://www.le.ac.uk/ieh/]
- de Pedro-Cuesta J, Gudmundsson G, Abraira V, Gudmundsson G, Love AT, Tulinius H, et al: Whooping cough and Parkinson's disease. Int J Epidemiol. 1996, 25: 1301-1311. 10.1093/ije/25.6.1301.View ArticlePubMedGoogle Scholar
- Wermuth L, Joensen P, Bünger N, Jeune B: High prevalence of Parkinson's disease in the Faroe Islands. Neurology. 1997, 49: 426-432.View ArticlePubMedGoogle Scholar
- Pedro-Cuesta J: Studies on the prevalence of Paralysis Agitans by tracer methodology. Acta Neurol Scand. 1987, 75: 101-106. 10.1111/j.1600-0404.1987.tb07902.x.View ArticleGoogle Scholar
- EPER. 2006, Ref Type: Electronic Citation, [http://eper.ec.europa.eu/eper/]
- García-Pérez J, Boldo E, Ramis R, Pollán M, Pérez-Gómez B, Aragonés N, et al: Description of industrial pollution in Spain. BMC Public Health. 2007, 7: 40-10.1186/1471-2458-7-40.View ArticlePubMedPubMed CentralGoogle Scholar
- López-Abente G, Ramis R, Pollán M, Aragonés N, Pérez-Gómez B, Gómez-Barroso D, et al: Atlas municipal de mortalidad por cáncer en España, 1989-1998. 2006, Madrid: Instituto de Salud Carlos IIIGoogle Scholar
- Clayton D, Kaldor J: Empirical Bayes estimates of age-standardized relative risks for use in disease mapping. Biometrics. 1987, 43: 671-681. 10.2307/2532003.View ArticlePubMedGoogle Scholar
- Besag J, York J, Molliè A: Bayesian image restoration, with applications in spatial statistics. Annals of the Institute of Statistics and Mathematics. 1991, 43: 1-59. 10.1007/BF00116466.View ArticleGoogle Scholar
- Clayton DG, Bernardinelli L, Montomoli C: Spatial correlation in ecological analysis. Int J Epidemiol. 1993, 22: 1193-1202. 10.1093/ije/22.6.1193.View ArticlePubMedGoogle Scholar
- Gilks WR, Richardson S, Spiegelhalter DJ: Markov Chain Monte Carlo in Practice. 1996, London: Chapman HallGoogle Scholar
- Spiegelhalter D, Thomas D, Best N, Gilks W: Bayesian inference using Gibbs sampling. Version 0.50. 1996, Cambridge: MRC: Biostatistics UnitGoogle Scholar
- Smith BJ: Bayesian Output Analysis Program (BOA), Version 0.99.1 for S-PLUS and R. 2001, Ref Type: Electronic Citation, [http://www.public-health.uiowa.edu/BOA]Google Scholar
- Richardson S, Thomson A, Best N, Elliott P: Interpreting posterior relative risk estimates in disease-mapping studies. Environ Health Perspect. 2004, 112: 1016-1025.View ArticlePubMedPubMed CentralGoogle Scholar
- López-Abente G, Pollán M, Aragonés N, Pérez B, Llácer A, Pérez J, et al: Tendencias de la Mortalidad en España, 1952-1996. Efecto de la edad, de la cohorte de nacimiento y del periodo de muerte. 2002, Madrid, Spain: Instituto de Salud Carlos IIIGoogle Scholar
- Del Barrio JL, de Pedro-Cuesta J, Boix R, Acosta J, Bergareche A, Bermejo F, et al: Dementia, Stroke and Parkinson's Disease in Spanish Populations: A Review of Door-to-Door Prevalence Surveys. Neuroepidemiology. 2005, 24: 179-188. 10.1159/000085138.View ArticlePubMedGoogle Scholar
- Benito-León J, Bermejo-Pareja F, Morales-Gonzalez JM: Incidence of Parkinson's disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004, 62: 734-741.View ArticlePubMedGoogle Scholar
- Burguera JA, Catalá J, Taberner P, Muñoz R: Mortalidad por enfermedad de Parkinson en España (1980-1985). Distribución por edades, sexo y áreas geográficas. Neurología. 1992, 7: 89-93.PubMedGoogle Scholar
- Limón C, García IA, Ortega A: Utilización de levodopa en España en el periodo 1982-1984. Información Terapéutica de la Seguridad Social. 1985, 9: 202-210.Google Scholar
- Cuadrado JI, de Pedro-Cuesta J, Abraira V, Stawiarz L, Ingesta A, Almazán J: Epidemiological assessment of levodopa use in Spain, 1990-1995. Persistent, low consumption in the South. Pharmacoepidemiol Drug Saf. 1999, 8: 433-445. 10.1002/(SICI)1099-1557(199910/11)8:6<433::AID-PDS451>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al: Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997, 62: 10-15. 10.1136/jnnp.62.1.10.View ArticlePubMedPubMed CentralGoogle Scholar
- Lopez S: Prevalencia de la enfermedad de Parkinson. Neurología. 1993, 8: 328-Google Scholar
- Manubens JM, Martínez-Lage JM, Lacruz F: Prevalencia de la enfermedad de Parkinson y otro tipos de parkinsonismo en el anciano. Neurología. 1993, 8: 399-Google Scholar
- Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R: Prevalence of PD and other types of Parkinsonism in three elderly populations of Central Spain. Mov Disord. 2003, 18: 267-274. 10.1002/mds.10362.View ArticlePubMedGoogle Scholar
- Clavería LE, Duarte J, Sevillano MD, Pérez-Sempere A, Cabezas C, Rodríguez F, et al: Prevalence of Parkinson's disease in Cantalejo, Spain: A door-to-door survey. Mov Disord. 2002, 17: 242-249. 10.1002/mds.10087.View ArticlePubMedGoogle Scholar
- Bergareche A, De la PE, López de MA, Sarasqueta C, De AA, Poza JJ, et al: Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. J Neurol. 2004, 251: 340-345. 10.1007/s00415-004-0333-3.View ArticlePubMedGoogle Scholar
- Seijo-Martínez M, Castro del RM, Paz EJ, Sobrido Gómez MJ, Rodríguez Á, Suárez PR, et al: Parkinsonismo y enfermedad de Parkinson en la Isla de Arosa (Pontevedra): prevalencia en la población anciana. Neurologia. 2005, 20: 517-Google Scholar
- Errea JM, Ara JR, de Pedro-Cuesta J: Prevalence of Parkinson's Disease in Lower Aragon, Spain. Mov Dis. 1999, 14: 596-604. 10.1002/1531-8257(199907)14:4<596::AID-MDS1008>3.0.CO;2-U.View ArticleGoogle Scholar
- Moreno-Zumalde J: Bilbao: Declive industrial, regeneración urbana y reactivación económica. 2005, Bilbao: Instituto Vasco de Administración Pública (Oñati)Google Scholar
- Llorente GA, Ferra A, Ruiz X, Albaigés J: Accumulation and distribution of hydrocarbons, polychlorobyphenyls and DDT in tissues of three species of Anatidae from the Ebro Delta (Spain). Arch Environ Contam Toxicol. 1987, 16: 563-572. 10.1007/BF01055812.View ArticlePubMedGoogle Scholar
- Porte C, Albaigés J: Bioaccumulation patterns of hydrocarbons and polychlorinated biphenyls in bivalves, crustaceans and fishes. Arch Environ Contam Toxicol. 1994, 26: 273-281. 10.1007/BF00203552.View ArticlePubMedGoogle Scholar
- Sala M, Sunyer J, Otero R, Santiago-Silva M, Grimalt J: Organochlorine in the serum of inhabitants living near an electrochemical factory. Occup Environ Med. 1999, 56: 152-158. 10.1136/oem.56.3.152.View ArticlePubMedPubMed CentralGoogle Scholar
- Sunyer J, Herrero C, Ozalla D, Sala M, Ribas-Fitó N, Grimalt J, et al: Serum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene. Environ Health. 2002, 1: 1-8. 10.1186/1476-069X-1-1.View ArticlePubMedPubMed CentralGoogle Scholar
- Sala M, Ribas-Fitó N, Cardo E, de Muga ME, Marco E, Mazón C, et al: Levels of hexachlorobenzene and other organochlorine compounds in cord blood: exposure across placenta. Chemosphere. 2001, 43: 895-901. 10.1016/S0045-6535(00)00450-1.View ArticlePubMedGoogle Scholar
- Ribas-Fitó N, Torrent M, Carrizo D, Júlvez J, Grimalt JO, Sunyer J: Exposure to hexachlorobenzene during pregnancy and children's social behavior at 4 years of age. Environ Health Perspect. 2007, 115: 447-450.View ArticlePubMedGoogle Scholar
- Carrizo D, Ribas-Fitó N, Torrent M, Sunyer J: In utero post-natal accumulation of organochlorine compounds in children under different environmental conditions. J Environ Monit. 2007, 9: 523-529. 10.1039/b700247e.View ArticlePubMedGoogle Scholar
- García-Pérez J, Boldo E, Ramis R, Pérez-Gómez B, Pollán M, Aragonés N, et al: Cancer mortality and industrial pollution in Spain. Abstract Book ISEE/ISEA International Conference on Environmental Epidemiology and Exposure. 204-Google Scholar
- Monge-Corella S, García-Perez J, Aragonés N, Pollán M, Perez-Gómez B, López-Abente G: Lung cancer mortality in towns near paper, pulp and board industries in Spain: a point source pollution study. BMC Public Health. 2008, 8: 288-10.1186/1471-2458-8-288.View ArticlePubMedPubMed CentralGoogle Scholar
- Dick FD, De PG, Ahmadi A, Osborne A, Scott NW, Prescott GLJ, et al: Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup Environ Med. 2007, 64: 673-680. 10.1136/oem.2006.032078.View ArticlePubMedPubMed CentralGoogle Scholar
- Adler CH: Differential diagnosis of Parkinson's disease. Med Clin North Am. 1999, 83: 349-367. 10.1016/S0025-7125(05)70108-5.View ArticlePubMedGoogle Scholar
- Tanner CM: Occupational and environmental causes of parkinsonism. Occup Med. 1992, 7: 503-513.PubMedGoogle Scholar
- Riley DE: Secondary parkinsonism. Parkinson's Disease and Movement Disorders. Edited by: Jankovic J, Tolosa E. 1998, London: Williams and Wilkins, 317-339.Google Scholar
- Mariussen E, Fonnum F: The effect of polychlorinated biphenyls on the high affinity uptake of the neurotransmitters dopamine, serotonine, glutamate and GABA into rat brain synaptosomes and vesicles. Toxicology. 2001, 159: 11-21. 10.1016/S0300-483X(00)00374-7.View ArticlePubMedGoogle Scholar
- Seegal RF: PCBs and dopamine function-Neurological effects of polychlorinated biphenyls: Does occupational exposure alter dopamine-mediated function? Parkinson's disease: The life cycle of the dopamine neuron. Ann NY Acad Sci. 2003, 991: 322-325.View ArticleGoogle Scholar
- Seegal RF, Brosch KO, Okoniewski RJ: Coplanar PCB congeners increase uterine weight and frontal cortex dopamine in the developing rat: implications for developmental neurotoxicity. Toxicol Sci. 2005, 86: 125-131. 10.1093/toxsci/kfi174.View ArticlePubMedGoogle Scholar
- Caudle WM, Richardson JR, Delea KC, Guillot TS, Wang M, Pennell KD, et al: Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. Toxicol Sci. 2006, 92: 490-499. 10.1093/toxsci/kfl018.View ArticlePubMedGoogle Scholar
- Mauri A, Asensio M, Jiménez A, Huerta JR, Redondo MJ, del VV: Familial Parkinson's Disease. Neurología. 1990, 5: 45-47.PubMedGoogle Scholar
- Mutch WJ, Smith WC, Scott RF: A screening and alerting questionnaire for parkinsonism. Neuroepidemiology. 1991, 10: 150-156. 10.1159/000110261.View ArticlePubMedGoogle Scholar
- Sevillano-García MD, Cuadrado-Gamarra JI, de Pedro-Cuesta J: Enfermedad de Parkinson en España: evidencias de infradiagnóstico y puntos de partida para su reducción. Rev Neurol. 1999, 29: 881-883.PubMedGoogle Scholar
- Migracion y estructura regional. 1968, Instituto Nacional de Estadística. Madrid, 55-66.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/9/445/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.